Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

Cited by (760)

Items 601–700 of 760

1. WITHDRAWN: Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
   Xudong Zhu, Tong Zhu, Xi Gu · 2025 · Annals of Oncology · Retracted
2. Prognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole
   Eyyüp Çavdar, Kubilay Karaboyun, Yakup İriağaç · 2025 · Bratislavské lekárske listy/Bratislava medical journal
3. Study protocol to assess clinical outcomes of breast cancer and its relationship with access to healthcare in Brazil—BREAST trial (BRaziLian outcomE for metAStatic breasT cancer): a prospective observational study in HER2-negative/hormone receptor-positive metastatic disease
   Vanessa Monteiro Sanvido, Lucíola de Barros Pontes, Rachel HV Machado, Jackeline Oliveira Gomes, Letícia Galvão Barbante, Marina Lazzari Nicola, Samira Martins Tokunaga, Tamiris Abait Miranda, Lígia Nasi Laranjeira, Karina Leal Negrelli et al. · 2025 · BMJ Open
4. Consenso sobre el diagnóstico y tratamiento del cáncer de mama: enfoque oncológico de la Asociación de Mastología de Antioquia
   Mauricio Lema, Fernando Herazo, Jorge Egurrola, Diego Moran Ortiz, Javier Cuello López, Néstor Eduardo Llinás Quintero, Diego Mauricio Gonzáles Ramírez, Andrés Yepes, Camilo Vallejo Yepes, Marcela Bermúdez Castrillón et al. · 2025 · Revista Colombiana de Hematología y Oncología
5. Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom
   Vanessa Castagnaviz, Anna Fenzl, Michael Gnant, Rupert Bartsch · 2025 · Wiener klinische Wochenschrift
6. Incidence and Outcomes of Atrial Arrhythmia with CDK4/6 Inhibitors in HR-Positive / HER2-Negative Breast Cancer
   Nathaniel E Davis, Joerg Herrmann, David O. Hodge · 2025 · medRxiv
7. Desmoid-Type Fibromatosis Masquerading as Disease Progression in Metastatic Breast Cancer in a Patient on Ribociclib Therapy: A Case Report
   Ha Rim Ahn, Ae Ri Ahn, Hyun Jo Youn · 2025 · Journal of Breast Cancer
8. Discordance in Immunohistochemistry Results in Breast Pathologies: Effect of Chemotherapy, Specimen Characteristics, or Pathology Center?
   Mustafa Ersoy · 2025 · Clinical Medicine Insights Oncology
9. Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis
   Alaa N. Shahbar · 2025 · Journal of Oncology Pharmacy Practice
10. Time-varying hazard rates reveal patterns of progression in HR+/HER2– metastatic breast cancer: Towards risk-adapted monitoring
    Linda Cucciniello, Fabiola Giudici, Lorenzo Foffano, Alessandra Franzoni, Brenno Pastò, Elisabetta Molteni, Serena Della Rossa, Gaetano Pascoletti, Simon Spazzapan, Lorena Musco et al. · 2026 · Translational Oncology
11. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies
    Eric Hahnen, Jan Hauke, Karen A. Gelmon, Frederik Marmé, Corinna Ernst, Miguel Martín, Michael Untch, Herve R. Bonnefoi, Erik S. Knudsen, Seock‐Ah Im et al. · 2025 · JCO Precision Oncology
12. Palbosiklib–letrozol ve ribosiklib–letrozol kombinasyonlarının metastatik HR+ / HER2- meme kanserinde birinci basamak tedavide etkinlik ve güvenlilik açısından karşılaştırılması
    Salih Tünbekici, Pınar Gürsoy, Erdem Göker · 2025 · Ege Tıp Dergisi
13. Group-Penalized Exponential Tilt Model for Identification of Differentially Methylated Genes in Epigenetic Association Studies
    Dan Huang, Hye‐Rim Park, Hokeun Sun · 2025 · Journal of Computational Biology
14. Metastatic Mammary-Like Adenocarcinoma of the Vulva Responding to Cyclin-Dependent Kinase (CDK) Inhibitor: A Case Report and Literature Review
    Filipa Pereira, Joana Liz-Pimenta, Mariana Rei · 2025 · Cureus
15. A Single-Cell Atlas of the Breast Cancer Microenvironment Identifies Subtype-Specific Tumor-Immune Landscapes and Vulnerabilities
    Liron Zisman Schachter, Asaf Pinhasi, K. Yizhak · 2025 · bioRxiv
16. CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study
    Palma Fedele, Matteo Landriscina, Lucia Moraca, Antonio Cusmai, Antonio Gnoni, Antonella Licchetta, Laura Lanotte, Maria Nicla Pappagallo, Assunta Melaccio, Guido Giordano et al. · 2025 · Cancers
17. Efficacy and toxicity of CDK 4/6 inhibitors in real clinical practice in patients with HR+ Her2new negative metastatic breast cancer
    L.V. Krivolapova, Anastasia S. Mochalova, Н. Б. Корчажкина, Mikhaĭlova Aa, Sergey O. Popov, D G Tagabilev, Olga V. Dymova, E V Batukhtina, V.O. Meshcherin, Аверина Наталья Алексеевна · 2025 · P A Herzen Journal of Oncology
18. Impact of Targeted Therapy on Progression-Free Survival in Breast Cancer: A Decade of Evidence from Randomized and Clinical Trials
    Oladipo Gideon Adesina, Femi Nwagwuogbe · 2025 · medRxiv
19. A functional map of CDK-drug interactions at single amino acid resolution
    Samuel I. Gould, Jonuelle Acosta, Luca Boscolo Bielo, Alinur Jaboldinov, Grace A. Johnson, Manuel E. Contreras, Alexandra N. Wuest, Emmanuel Brémont, Mohammed A. Toure, Yichen Xiang et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
20. Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
    Jessica Armand, Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Kevin M. Kalinsky, Hee Won Yang · 2025 · eLife
21. Machine Learning Identifies Glycosphingolipid Signature Linking Immune Dysregulation and Clinical Prognosis in Uveal Melanoma
    Haoran Guo, Bai Li, Zhi Zhang · 2025 · Research Square
22. A UK study of the experiences, information needs and attitudes to clinical research among patients living with secondary breast cancer in the UK: A prospective co-developed study
    Lesley Stephen, Janet Dunn, Claire E. Balmer, Nada I. Elbeltagi, Sophie J. Gasson, Ellen Copson, Carlo Palmieri · 2025 · The Breast
23. Feasibility of a Smart Label–Enabled Remote Therapeutic Monitoring Intervention to Support Cyclin-Dependent Kinase 4/6 Inhibitor Adherence in Breast Cancer Care
    Ilana Graetz, Sara Arshad, Clara Cai, Samuel Hernandez, Tamar Sapir, Jeffrey Carter, Cherilyn L. Heggen, Kelly E. McKinnon, Freddie Yang, Gelareh Sadigh et al. · 2025 · JCO Clinical Cancer Informatics
24. Cost-effectiveness analysis of ribociclib versus palbociclib as a first line theraphy in HR+/HER2- advanced breast cancer: evidence from the Chilean public health system
    Carlos Balmaceda, N. Armijo, M. Espinoza · 2025 · Expert Review of Pharmacoeconomics & Outcomes Research
25. Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variant
    Maartje A. C. Schreurs, Muriel A. Adank, Bernadette A. M. Heemskerk‐Gerritsen, Antoinette Hollestelle, Nyrée Smallenbroek, Christie J. van Asperen, Margreet G.E.M. Ausems, Irma van de Beek, Geertruida H. de Bock, Ingrid A Boere et al. · 2025 · The Breast
26. Rethinking cancer clinical trial eligibility—Inclusion is a scientific and moral imperative
    Nupur Mittal · 2025 · Cancer
27. Cost-effectiveness analysis of ribociclib versus abemaciclib as first-line treatments for postmenopausal women with HR+/HER2– advanced breast cancer: a Medicare perspective
    Paolo Tarantino, Sarah LeNoir Sammons, Vijayakrishna K. Gadi, Purnima Pathak, Gary Mark Sopher, Thomas E. Delea, Daniel Stellato · 2025 · Journal of Medical Economics
28. Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2– advanced breast cancer in postmenopausal women: analysis from a Medicare perspective
    Sarah LeNoir Sammons, Paolo Tarantino, Vijayakrishna K. Gadi, Purnima Pathak, Gary Mark Sopher, Thomas E. Delea, Daniel Stellato · 2025 · Journal of Medical Economics
29. A novel mechanism of immunoevasion by ER+ breast cancer
    Claudia Galassi, Lorenzo Galluzzi · 2025 · Trends in Immunology
30. Therapeutic Patterns and Survival Outcomes in 939 HER2-Negative Metastatic Breast Cancer Patients: 10-Year Results from the Italian GIM 13-AMBRA Cohort
    A. Svensson, B. Karlsson, E. Nilsson · 2024 · Asian journal of Current Research in Clinical Cancer
31. A phase IV prospective study of efficacy and safety of Ribociclib and letrozole in first-line in Older women (≥70 years) with hormone receptor-positive HER2-negative advanced Breast cancer: The RibOB study
    Van Houdt, Maxime, De Nys, Louis, Kenis, Cindy et al. · 2025 · Lirias
32. Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors
    Justine Dutheil, Victor Pereira, Cyril Boisson, Laura Mansi, Marie‐Justine Paillard, Fernando Bazán, L. Chaigneau, Erion Dobi, Julien Viot, Guillaume Meynard et al. · 2025 · Breast Cancer Research
33. Contemporary Approaches to Breast Cancer Management: An Evidence Synthesis Guiding Clinical Practice and Patient Care.
    Naseralla Juma Elsaadi Suliman, Marei Omar Al-Jahany, Mohamed A Moftah · 2025 · Benghazi University Medical Journal
34. Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms
    Diana Lüftner, Hans-Christian Kolberg, A Hartkopf, Tanja Natascha Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter Andreas Fasching, Christian Jackisch, Frederik Marme et al. · 2025 · Senologie - Zeitschrift für Mammadiagnostik und -therapie
35. Nephrotoxicity secondary to CDK 4/6 inhibitors in advanced breast cancer patients and its impact on survival
    Tugay Avcı, Ahmet Anıl Altunbaş, Mustafa Şahbazlar, Ferhat Ekinci, Atike Pınar Erdoğan · 2026 · Therapeutic Advances in Medical Oncology
36. Analysis of Risk Factors for Abemaciclib-Induced Diarrhea
    Kenta Takeuchi, Aya Murakami · 2026 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
37. Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2− advanced breast cancer treated with CDK4/6 inhibitors
    Rosalba Torrisi, Federica Giugliano, Laura Giordano, Giuseppe Saltalamacchia, Flavia Jacobs, Ambra Carnevale Schianca, Monica Milano, Nadia Bianco, Claudia Anna Sangalli, De Sanctis R et al. · 2026 · The Oncologist
38. Pursuit of precision oncology in the treatment of metastatic hormone receptor–positive breast cancer: Making strides or barely moving?
    Ilana Miriam Schlam, Ajay Dhakal · 2026 · CA A Cancer Journal for Clinicians
39. Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center
    Alfredo S Golemba, Pablo Mandó, Adriana Lucia Jimenez Bolaño, S. P. Rodriguez Torres, Rusvelt Vargas Moranth, Astor Alfonso Aguirre Santamaría · 2026 · Cureus
40. Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study
    Marina Elena Cazzaniga, Stefania Galimberti, Francesca Fulvia Pepe · 2026 · BMC Cancer
41. Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2– metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study
    Claudia Noto, Lorenzo Foffano, Fabiola Giudici, Elisabetta Molteni, Alessandra Franzoni, Martina Tessitori, Linda Cucciniello, Silvia Bolzonello, Lucia Da Ros, Lucia Bortot et al. · 2026 · The Breast
42. Perioperative Management of Targeted and Immunologic Agents in Neurosurgical Oncology
    Maged T Ghoche, Kenji Miki, Fanen Yuan · 2026 · Neurosurgery
43. Cardiovascular toxicity of cyclin-dependent kinase 4 and 6 inhibitors
    Jingjiao Zhang, Zhongjing Ma, Pan Chen, Lili Tian, Fengqi Fang, Jia Li · 2025 · Journal of Cardio-oncology
44. Post-operative survival and use of systemic therapy in metastatic long-bone disease: 12 years of institutional experience
    Tom Maarten Groot, Joris R.H Hendriks, Michelle R. Shimizu et al. · 2026 · Journal of bone oncology
45. Metastatic breast cancer outcome in a real-world setting: analysis for long-term survival and curability in a prospective dataset
    Arlene Chan, Mengdie Zhou, Mridula Arun, Amanda Goddard, HuiJun Chih · 2026 · The Oncologist
46. Breast cancer and liver metastases: an imaging perspective on the potential of resectability
    Erik Baubeta, Hanna Valind, Oskar Hagberg, Kristina Lång, Anna-Maria Larsson, Bodil Andersson, Hanna Sartor · 2026 · Acta Radiologica
47. Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2− bone-only metastatic breast cancer
    Adam Brufsky, Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron Cohen, Melissa Estévez, Paul Henri Cottu, Giuseppe Curigliano, Hope S. Rugo · 2026 · The Breast
48. Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study
    Pablo Tolosa, Isabel García-Fructuoso, Tomás Pascual, Olga Martínez-Sáez, Juan Miguel Cejalvo, Sònia Servitja, María Fernández-Abad, Javier David Benítez Fuentes, Fara Brasó‐Maristany, Ester Sanfeliu et al. · 2026 · Breast Cancer Research and Treatment
49. Treatment Outcomes in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Patients with and without Progression after Completion of Reimbursed Cyclin-dependent Kinase 4/6 Inhibitors in Taiwan: A Single-institution Experience
    Yi-Hsuan Hsu, Po-Shen Yang, Yuan‐Ching Chang, Hung-Bun Lam, F. Lee, Chia‐Yen Hung, Johnson Lin, Nei-Wen Su, Yi‐Hao Chiang, Huan-Chao Lin et al. · 2026 · Journal of Cancer Research and Practice
50. A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer
    L.Boscolo Bielo, Dario Trapani, Pedram Razavi, Sarat Chandarlapaty, Yinxiu Zhan, G. Curigliano · 2026 · ESMO Open
51. Le trastuzumab déruxtécan en première ligne de traitement des cancers du sein récepteurs hormonaux positifs et HER2 faible ou ultra-faible au stade avancé
    Emma Ferber, Nicolas Kiavué · 2026 · Bulletin du Cancer
52. Therapeutic Challenges of a Renal Collision Tumour Comprising Clear Cell Renal Cell Carcinoma and Metastatic Breast Carcinoma: A Case Report
    AJP Fulton, AY Warren, Sona J. Appukutty et al. · 2026 · Research Square
53. HR+/HER2− metastatik meme kanserinde CDK4/6 inhibitörü alan hastalarda hematolojik ve biyokimyasal parametreler, tedaviye bağlı toksisite ve sağkalım ilişkisi: Retrospektif tek merkezli analiz
    Pınar Peker, Seher Selvi, Berna Bozkurt Duman, Timuçin Çil · 2026 · Ege Tıp Dergisi
54. TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer
    S. Jacob, Erica L. Mayer, N. Kacik, Anna Maria Storniolo, C. Isaacs, Ingrid A. Mayer, Vered Stearns, Rita Nanda, Julie R. Nangia, A.J. Chien et al. · 2026 · ESMO Open
55. Physiologically-Based Pharmacokinetics of Ribociclib Drug–Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer
    Y. Ji, Felix Huth, Craig Wang, Hilmar Schiller, François Pierre Combes, John Crown, Peter Andreas Fasching, Juan Pablo Zarate, Michael Untch · 2026 · Pharmaceuticals
56. 転移・再発乳がんにおける分子標的治療時代の治療戦略
    智子 栗田 · 2026 · Nihon Ika Daigaku Igakkai Zasshi
57. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
    Mustafa Seyyar, Ali̇ Kalem, Mürsel Salı, Berkan Karabuğa, Taha Koray Sahin, Ahmet Kürşad Dişli, Alper Türkel, Berkan Karadurmuş, Ece Şahin Hafızoğlu, Nilüfer Avcı et al. · 2026 · Research Square
58. Outcomes of CDK4 /6 Inhibitor‐Based Therapy in Premenopausal HR +/ HER2 − Metastatic Breast Cancer: Real World Data From A Multicenter Study
    Hatice Odabaş, Omar Alomarı, Seval Orman, Nadiye Sever, Esmanur Kaplan Tüzün, Aydın Acarbay, Eda Erçin, Miray Aydoğan, Ali Kaan Güren, Muhammed Edib Mokresh et al. · 2026 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
59. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer
    Juan M. Alcantar, Fukai L. Chuang, David D Kim · 2026 · Cureus
60. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study
    Ahmet Fatih Oruç, İlknur Deliktaş Onur, Galip Can Uyar, Taha Koray Sahin, Salih Tünbekici, Ayşe Arslan Kapuci, Ece Ulukal Karancı, Fatih Kemik, Şafak Yıldırım Dişli, Öztürk Ateş et al. · 2026 · Scientific Reports
61. Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2− metastatic breast cancer in US routine clinical practice
    Hope S. Rugo, Adam Brufsky, Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, A. B. Cohen, Melissa Estévez, Filipa C. Lynce, Paul Henri Cottu et al. · 2026 · The Breast
62. Effectiveness and Safety of Acupuncture for Cancer-Related Cognitive Impairment: A Systematic Review and Meta-Analysis
    Hao Zhang, Juda Liu, Fang He, Kuojun Ren, Shengying Wang · 2026 · Journal of Integrative and Complementary Medicine
63. Patterns of Disease Progression in Advanced Breast Cancer Patients Treated With Cyclin D Kinase 4/6 Inhibitors: Prognostic and Therapeutic Implications
    Sudhir Kumar, Neha Pathak, Rossanna C. Pezo · 2026 · Clinical Breast Cancer
64. A scoping review investigating the influence of comorbidities on the use and outcomes of biological therapies in breast cancer
    Sophie Anne Trotter, Katie Crook, Dina Hesham hamed, Lynda Wyld, Janet Brown · 2026 · Journal of Geriatric Oncology
65. Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial
    Eduard Vrdoljak, Marija Pancirov, Josipa Flam, Dora Čerina, Matea Jakas Vučić, Marica Barać, Natalija Dedić Plavetić, Paula Podolski, Mladen Krnić, Žarko Bajić · 2026 · Cancers
66. Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer
    Yan Ji, F. Sun, M. Sato, Satoru Inoue, Yolanda Bi, Juan Pablo Zarate, Yen-Shen Lu · 2026 · Clinical Therapeutics
67. Clinical and demographic characteristics and treatment patterns of patients with HR+ HER2– locally advanced or metastatic breast cancer receiving CDK4/6 inhibitors in real-world clinical practice in Moscow: data from the ICEDORA study
    Игорь Евгеньевич Хатьков, I. I. Andreyashkina, Троценко Иван Дмитриевич, O. N. Matveeva, Violetta Reznikov · 2026 · Real-World Data & Evidence
68. Ribociclib as a key component of highly effective endocrine therapy regimens of early lines in metastatic HR+ HER2- breast cancer: A series of real-world clinical cases from the Russian Federation
    Л. В. Болотина, Ганьшина Инна Петровна, Anna L. Kornietskaya · 2026 · Journal of Modern Oncology
69. Expression du récepteur CD160 par les cancers du sein : caractérisation fonctionnelle et applications thérapeutiques potentielles
    Claire Scheffges · 2024 · theses.fr (ABES)
70. Thermal ablation of breast cancer liver metastases achieves durable control and prolongs chemotherapy-free survival in selected patients
    Niaz Ahmed, Alicia F. C. Okines, Sophie McGrath · 2026 · Research Square
71. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
    Zeliha Birsin, Ali Kaan Güren, Vali Aliyev, Murad Guliyev, Seda Jeral, Selin Cebeci, Emir Çerme, Murat Günaltılı, Hamza Abbasov, Ebru Çiçek et al. · 2026 · Breast Cancer Targets and Therapy
72. The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
    Stefania Crucitta, Paola Cinacchi, Irene Bargagna, Pamela Biondani, Elena Giontella, Michela Palleschi, Claudia Omarini, Lorenzo Belluzzi, Lucia Angelini, Icro Meattini et al. · 2026 · Therapeutic Advances in Drug Safety
73. Intestinal Organoid‐Based Mathematical Modeling Predicts Clinical Gastrointestinal Toxicity of Oral Oncology Drugs
    Carmen Pin, Deepa Maheshvare M., Louis Gall, Andrew Hall, Muireann Coen, Ambra Bianco, Shimeng Liu, Kenneth R. Pryde · 2026 · CPT Pharmacometrics & Systems Pharmacology
74. Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer
    Yehoda M. Martei, Kan Chen, Modesty Obasohan, Ronac Mamtani, Erin Aakhus, Lawrence N. Shulman, Rebecca A. Hubbard, Amy Clark · 2026 · JNCI Cancer Spectrum
75. CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy
    Xinming Su, Takayuki Kobayashi, Jingyu Xiang, Yalin Xu, Ayesha N. Shajahan‐Haq, Mahta Mardani, Suleyman Noordeen, Kaylee M. O'Donnell, Kristin A. Kwakwa, Dennis Guan et al. · 2026 · Journal of bone oncology
76. CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
    Mohammed S. Beshr, Ammar Fahaid, Rana Hasen Shembesh, Antonios Valachis, Matteo Lambertini, Laura Cortesi, Alzahraa Faris Alesawy, Ahmed Abraheem, Mohamed Farouq Alsharedi, Mohamed E Ali et al. · 2026 · The Lancet Oncology
77. Prognostic value of cachexia index in HR +/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
    Gül Sema Yıldıran Keskin, Gulsah Gedikli Turgut, Gizem Yildirim, Esmanur Kaplan Tüzün, Volkan Aslan, Musa Barış AYKAN, Semra İnce, N. Karadurmus · 2026 · BMC Cancer
78. Clinical features and management for CDK4/6 inhibitor-DILI
    Mar Riveiro‐Barciela, P. Pinon Esteban, Kreina Sharela Vega-Cano, Beatriz Mateos, Elena López Miranda, Pablo Jara, M Casado Martín, Sonia Alonso López, Magdalena Salcedo, Xavier Forns et al. · 2026 · JHEP Reports
79. Ten-year subtype survival and systemic–therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort study
    Javier Retamales, Ingiborg Araya, Eliana S. F. W. Abdelhay, Keyla Teresa Acosta Torres, Daniela Alves da Quinta, Elsa B. Alcoba, Isabel Alonso, Nora Artagaveytia, Renata Binato, Alicia Bravo et al. · 2026 · The Lancet Regional Health - Americas
80. Extensive Cutaneous and Scalp Metastases From Hormone Receptor-Positive Breast Cancer Successfully Treated With CDK4/6 Inhibitor Therapy: A Case Report
    Ricardo Fernández-Ferreira, Verónica Bautista‐Piña, Mireya Barragán‐Dessavre, G. Cruz-Morales, Jesús Montaño-Hernández, Alejandro Salas-Pérez, Rosa María Vicuña-González, R. Anaya Jimenez, Regina Moreno-López, Sandra-María García-López et al. · 2026 · Cureus
81. Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy
    Akshara Singareeka Raghavendra, Wei Qiao, Yu Shen, Senthil Damodaran, Kelly K. Hunt, Debu Tripathy · 2026 · The Lancet Regional Health - Americas
82. Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy
    Sònia Pernas, Xavier Forns, Olga Martínez-Sáez, Raúl J Andrade, Alberto Amador, Elena López-Miranda, Begoña Bermejo, Beatriz Mateos, Mónica Cejuela Solís, María José Villanueva et al. · 2026 · Clinical & Translational Oncology
83. Clinical and Demographic Characteristics of Patients With Long-Term Disease Control With First-Line Endocrine Therapy Alone for Hormone Receptor Positive, HER2 Negative, Metastatic Breast Cancer
    Gretchen Genevieve Kimmick, Asal Pilehvari, Wen You, Gloribel Bonilla, Roger T. Anderson · 2026 · Clinical Breast Cancer
84. Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India
    Anindya Mukherjee, Pankaj Goyal, Rupal Tripathi, Sumit Goyal, Ullas Batra, Vineet Talwar, Varun Goel, Arpit Jain, Shekhar Saha, Sneha Jatan Bothra et al. · 2026 · PLoS ONE
85. Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals
    Rita Freitas, Tiago Barroso, Sofia Azambuja Braga, Catarina C Santos, Marta Batista, Andreia Filipa Chaves, Sara Carla Moura Cabral, Ana Fortuna, Vanessa Patel, João Araújo et al. · 2026 · Cureus
86. Prognostic Role of Uric Acid-to-Albumin Ratio in Patients with Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Talat Aykut, Mehmet Zahid KOÇAK, Oğuzhan Yıldız · 2026 · Journal of Clinical Medicine
87. Evolving Treatment Paradigms in Hormone Receptor–Positive, Human Epidermal Growth Factor 2–Negative Metastatic Breast Cancer
    Sara Soliman, Ryan Zitter, Stephanie Walker, Stephen J. Chmura, Alexandru E. Eniu, Stephanie L. Graff · 2026 · American Society of Clinical Oncology Educational Book
88. Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China
    Xianan Guo, Panni Li, Shiyao Hu, Yuqin Ding, Bojian Xie, Yangjun Cai, Huihui Chen, Xiawei Li, Shiwei Guo, Yanyan Wang et al. · 2026 · BMC Cancer
89. Efficacy and Toxicity of CDK4/6 Inhibitors in Early and Metastatic HR+/HER2− Breast Cancer: An Updated Meta-Analysis of Phase III Trials
    Ravneet K Dhanoa, Sumin Thapa, Pragnan Kancharla, Shweta Kurian · 2026 · Cancers
90. CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan–Meier-reconstructed individual-level data
    Jasmina Veta Darkovski, Isabella Ferreira Michelon, Gabriela Gazzoni, Isadora Mamede, Yujin Jeong, Ludimila L. Cavalcante · 2026 · Breast Cancer Research
91. Fovinaciclib for First-Line Therapy of Advanced Breast Cancer
    Peng Yuan, Liu Y, Wei Li, Huiping Li, Zhongsheng Tong, Jing Cheng, Mingjuan Zhang, Jinlu Shan, Jincai Zhong, Tienan Yi et al. · 2026 · JAMA Oncology
92. Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals
    Robin Forrest, Ajay Kumar Aggarwal, Michelle Tregear, Melanie Wynne, Holly Fernandez Lynch, Anita Katharina Wagner, Emily Jackson, Huseyin Naci · 2026 · JAMA Network Open
93. First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
    Marcus Schmidt, M.A.M. Thill, J. Rey, Beate Rautenberg, V. Bjelic-Radisic, T. Decker, Joachim Rom, M. Koegel, K. Lübbe, Axel Nacke et al. · 2026 · ESMO Open
94. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
    Mustafa Seyyar, Ali̇ Kalem, Mürsel Salı, Berkan Karabuğa, Taha Koray Şahin, Ahmet Kürşad Dişli, Alper Türkel, Berkan Karadurmuş, Ece Şahin Hafızoğlu, Nilüfer Avcı et al. · 2026 · Current Oncology
95. Thermal Ablation of Breast Cancer Liver Metastases Is Associated with Durable Local Control and Chemotherapy-Free Intervals in Selected Patients
    Niaz Ahmed, Alicia F. C. Okines, Sophie McGrath, M. Parton, Emma Kipps, Nicholas C. Turner, Edward William Johnston, Stephen R.D. Johnston, Nicos Fotiadis · 2026 · Cancers
96. Clinicopathological discordance and survival outcomes in 154 breast cancer patients with pulmonary metastasis in a real-world setting
    Ying Yan, Yifei Chen, Lijun Di, Xu Liang, Bin Shao, Hanfang Jiang, Guohong Song, Huiping Li · 2026 · Discover Oncology
97. Survival in the SONIA Trial
    Taichi Kurose, Akihiko Shimomura, C Shimizu · 2026 · JAMA Oncology
98. Clinical Characteristics and Prognostic Risk Factors in Breast Cancer With Liver Metastasis
    Dandan Yu, Chengjun Zhu, Sujin Yang, Dandan Wang, Xiaoxiang Guan · 2026 · The Breast Journal
99. Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer
    Yan Ji, Craig Wang, François Pierre Combes, Yu-Yun Ho, Peter Andreas Fasching, M Untch, Juan Pablo Zarate, John Paul Crown · 2026 · Clinical Pharmacokinetics
100. Efficacy and tolerability of CDK 4/6 inhibitors in HR-positive HER2-negative de novo metastatic breast cancer patients aged ≥ 70 years
     Muhammed Mustafa Atçı, Mert Erciyestepe, Kayhan Ertürk · 2026 · BMC Cancer